160 related articles for article (PubMed ID: 33755176)
1. Unexpected Cytomegalovirus (CMV) Replication Kinetics in CMV Donor-Seropositive, Recipient-Seronegative Liver Transplant Recipients Receiving Preemptive Antiviral Therapy.
Singh N; Winston DJ; Razonable RR; Marshall Lyon G; Silveira FP; Wagener MM; Limaye AP
J Infect Dis; 2022 Feb; 225(3):436-442. PubMed ID: 33755176
[TBL] [Abstract][Full Text] [Related]
2. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
[TBL] [Abstract][Full Text] [Related]
3. Association of HHV-6 With Outcomes in CMV-seronegative Liver Transplant Recipients With CMV-seropositive Donors Receiving Preemptive Antiviral Therapy.
Singh N; Winston DJ; Razonable RR; Lyon GM; Huang ML; Jerome KR; Silveira FP; Wagener MM; Limaye AP
Transplantation; 2021 Nov; 105(11):2427-2434. PubMed ID: 33587431
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors for Cytomegalovirus Viremia following Liver Transplantation With a Seropositive Donor and Seronegative Recipient Receiving Antiviral Therapy.
Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Limaye AP
J Infect Dis; 2021 Mar; 223(6):1073-1077. PubMed ID: 32726431
[TBL] [Abstract][Full Text] [Related]
5. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
Singh N; Wannstedt C; Keyes L; Mayher D; Tickerhoof L; Akoad M; Wagener MM; Cacciarelli TV
Liver Transpl; 2008 Feb; 14(2):240-4. PubMed ID: 18236404
[TBL] [Abstract][Full Text] [Related]
6. Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients.
Sun HY; Cacciarelli TV; Wagener MM; Singh N
Transpl Immunol; 2010 Aug; 23(4):166-9. PubMed ID: 20609386
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients.
Tan SK; Waggoner JJ; Pinsky BA
J Clin Virol; 2015 Aug; 69():179-83. PubMed ID: 26209403
[TBL] [Abstract][Full Text] [Related]
8. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Preemptive Therapy Versus Prophylaxis in a Randomized Clinical Trial for the Prevention of Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors.
Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Limaye AP
Clin Infect Dis; 2021 Nov; 73(9):e2739-e2745. PubMed ID: 32712663
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients.
Liu AW; Jutivorakool K; Fisher CE; Rakita RM; Reyes JD; Bhattacharya RB; Jerome KR; Limaye AP
Transplantation; 2018 Apr; 102(4):632-639. PubMed ID: 29215460
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients.
Lisboa LF; Preiksaitis JK; Humar A; Kumar D
Transplantation; 2011 Nov; 92(9):1063-8. PubMed ID: 21878838
[TBL] [Abstract][Full Text] [Related]
12. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy.
Brennan DC; Garlock KA; Lippmann BA; Buller RS; Gaudreault-Keener M; Lowell JA; Miller SB; Shenoy S; Howard TK; Storch GA
J Am Soc Nephrol; 1997 Jan; 8(1):118-25. PubMed ID: 9013456
[TBL] [Abstract][Full Text] [Related]
13. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
Li L; Wang Y; Yan CH; Huang XJ
Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863
[No Abstract] [Full Text] [Related]
15. Real-world effectiveness of preemptive therapy (PET) for cytomegalovirus (CMV) disease prevention in CMV high-risk donor seropositive/recipient seronegative (D+R-) liver transplant recipients (LTxR).
Doss KM; Kling CE; Heldman MR; Singh N; Wagener M; Rakita RM; Fisher CE; Limaye AP
Transpl Infect Dis; 2023 Apr; 25(2):e14015. PubMed ID: 36734631
[TBL] [Abstract][Full Text] [Related]
16. Incidence of Cytomegalovirus disease and viral replication kinetics in seropositive liver transplant recipients managed under preemptive therapy in a tertiary-care center in Mexico City: a retrospective cohort study.
Fernández-García OA; García-Juárez I; Belaunzarán-Zamudio PF; Vilatoba M; Wisniowski-Yáñez A; Salomón-Ávila J; Bobadilla-Del-Valle M; Sifuentes-Osornio J; Cuellar-Rodríguez JM
BMC Infect Dis; 2022 Feb; 22(1):155. PubMed ID: 35164684
[TBL] [Abstract][Full Text] [Related]
17. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
J Clin Virol; 2015 Oct; 71():73-5. PubMed ID: 26318605
[TBL] [Abstract][Full Text] [Related]
18. Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation.
Jorgenson MR; Wong C; Descourouez JL; Saddler CM; Smith JA; Mandelbrot DA
Transpl Infect Dis; 2021 Aug; 23(4):e13617. PubMed ID: 33866643
[TBL] [Abstract][Full Text] [Related]
19. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients.
Jorgenson MR; Descourouez JL; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
Transpl Infect Dis; 2021 Aug; 23(4):e13693. PubMed ID: 34309158
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for high level cytomegalovirus viremia in liver transplant recipients and associated outcomes.
Kleiboeker HL; Jorgenson MR; Leverson GE; Rice JP; Saddler CM; Smith JA; Al-Adra D
Transpl Infect Dis; 2022 Aug; 24(4):e13898. PubMed ID: 35780512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
